Sacral Erector Spinae Plane Block(ESPB) in Lumbar Discectomy
Launched by BILGE OLGUN KELES · Aug 31, 2023
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This prospective, randomised, controlled, double-blind, single-centre study was approved by our Ethics Committee (KAEK2023/06). The investigators followed the Consolidated Reporting Trials Standards (CONSORT). It was conducted in patients undergoing elective lumbar discectomy, and informed consent was obtained from the patients. They were randomised using a closed envelope technique, opened by the physician performing the block. 54 patients were included in the study, divided into two groups of 27 patients as esp block (group 1) and control group (group 2), both groups underwent standard ge...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients over 18 years of age,
- • American Society of Anesthesiology(ASA) status 1-3 group
- Exclusion Criteria:
- • Patients who refused to participate in the study
- • Patients with known neuromuscular and haematological diseases
- • Allergy to local anaesthetics
- • Contraindications to regional anaesthesia
- • Anatomical changes in the lumbo-sacral region
About Bilge Olgun Keles
Bilge Olgun Keles is a dedicated clinical trial sponsor committed to advancing medical research through innovative study designs and rigorous protocols. With a focus on enhancing patient outcomes and ensuring safety, the organization collaborates with healthcare professionals and research institutions to facilitate the development of cutting-edge therapies. Leveraging a wealth of expertise in clinical operations and regulatory compliance, Bilge Olgun Keles aims to contribute to the scientific community by driving forward evidence-based solutions that address unmet medical needs. Their mission is rooted in a patient-centered approach, ensuring that all trials are conducted with the highest ethical standards and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Merkez, Giresun, Turkey
Patients applied
Trial Officials
Bilge Olgun Keleş, M.D.
Study Director
Giresun University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported